Allergy Mold Panel, Complete
The Allergy Mold Panel, Complete measures serum IgE to six clinically important fungal allergens—Alternaria, Aspergillus, Cladosporium, Penicillium, Candida, and Mucor—alongside total IgE. It confirms mould sensitisation in patients with perennial or seasonal respiratory symptoms linked to damp environments and supports the diagnosis of allergic bronchopulmonary aspergillosis when Aspergillus…
7
Biomarkers
Blood (serum)
Sample
3–5 business days
Turnaround
No
Fasting
What is the Mold Allergy Panel test?
The Allergy Mold Panel, Complete quantifies serum IgE antibodies to six clinically important fungal allergens: Alternaria alternata, Aspergillus fumigatus, Cladosporium herbarum, Penicillium notatum, Candida albicans, and Mucor racemosus, alongside total IgE. It is ordered to confirm mould sensitisation in patients with respiratory or cutaneous symptoms that correlate with damp indoor environments, outdoor exposure, or occupational contact with organic decay. Fungal allergy is often under-recognised. Unlike pollen, mould spores are present year-round indoors and peak outdoors in late summer and autumn in temperate climates. This panel identifies the specific moulds driving symptoms, distinguishes IgE-mediated allergy from other causes of rhinitis or asthma, and guides environmental control, pharmacotherapy, and in selected cases immunotherapy. For Aspergillus, the result also supports or excludes allergic bronchopulmonary aspergillosis, a condition that requires prompt recognition and treatment to prevent irreversible lung damage.
What does the Mold Allergy Panel test measure?
Alternaria alternata is a ubiquitous dematiaceous fungus found outdoors on decaying vegetation and indoors in damp environments. Sensitisation triggers mast-cell-bound IgE cross-linking upon allergen encounter, releasing histamine and other mediators. Alternaria is a major outdoor allergen in temperate climates and a known trigger of severe asthma.
Detection of Alternaria-specific IgE confirms sensitisation in patients with seasonal or perennial rhinitis, conjunctivitis, or asthma exacerbated by outdoor activity or damp weather. High titres correlate with increased risk of asthma exacerbations and may guide environmental control and immunotherapy decisions.
Aspergillus fumigatus is a thermotolerant saprophyte that releases abundant airborne conidia. IgE-mediated sensitisation can manifest as allergic rhinitis or asthma, and in susceptible individuals — particularly those with cystic fibrosis or asthma — as allergic bronchopulmonary aspergillosis (ABPA), a mixed type I and type III hypersensitivity disorder.
Aspergillus-specific IgE is elevated in ABPA, where it is accompanied by total IgE, eosinophilia, and pulmonary infiltrates. Isolated sensitisation without ABPA can still contribute to poorly controlled asthma. The result guides antifungal or corticosteroid therapy and distinguishes ABPA from invasive aspergillosis, which is not IgE-mediated.
Cladosporium herbarum is one of the most common airborne moulds worldwide, peaking in warm, dry weather. Its spores are small and easily inhaled, triggering IgE production in susceptible individuals. Cladosporium sensitisation often coexists with other mould and pollen allergies.
Cladosporium-specific IgE supports the diagnosis of seasonal or perennial allergic rhinitis and asthma when symptoms correlate with outdoor or indoor mould exposure. Because Cladosporium is so widespread, positive results are common but should be interpreted in the context of symptom timing and other sensitisations.
Penicillium species are common indoor moulds that thrive in water-damaged buildings, on spoiled food, and in damp basements. Penicillium notatum (also called Penicillium chrysogenum) releases allergenic proteins that induce IgE formation in sensitised individuals.
Detection of Penicillium-specific IgE confirms sensitisation in patients with perennial rhinitis or asthma worsened by indoor dampness. It is particularly relevant in occupational settings (e.g., food processing, agriculture) and in homes with visible mould or water damage.
Candida albicans is a commensal yeast of the human gut and mucosa. While invasive candidiasis is not IgE-mediated, IgE antibodies to Candida proteins can develop in atopic individuals and have been implicated in some cases of chronic urticaria, eczema, and respiratory symptoms, though the clinical significance of isolated Candida sensitisation remains debated.
Candida-specific IgE is occasionally elevated in patients with atopic dermatitis or chronic urticaria, and some practitioners consider it in the context of suspected 'fungal overload' syndromes, though robust evidence for the latter is limited. Interpretation should be cautious and correlated with clinical context rather than prompting antifungal treatment based on serology alone.
Mucor species are saprophytic zygomycetes found in soil, decaying organic matter, and occasionally indoor air in damp environments. IgE-mediated allergy to Mucor is less common than to Alternaria or Aspergillus but can occur in heavily exposed individuals.
Mucor-specific IgE is relevant in patients with unexplained respiratory allergy who have occupational or residential exposure to composting, agriculture, or water-damaged buildings. It is not associated with invasive mucormycosis, which occurs in immunocompromised hosts and is not IgE-mediated.
Total IgE reflects the sum of all circulating IgE antibodies, both allergen-specific and polyclonal. It is elevated in atopy, parasitic infection, some immunodeficiencies, and ABPA. While not specific, total IgE provides context for interpreting specific IgE results and is a required criterion in the diagnosis of ABPA.
Markedly elevated total IgE (>1000 kU/L) in the presence of Aspergillus-specific IgE, eosinophilia, and pulmonary infiltrates suggests ABPA. Moderate elevations are common in polysensitised atopic patients and add little diagnostic value in isolation, but serial monitoring can track disease activity in ABPA or guide omalizumab dosing.
Why is the Mold Allergy Panel test ordered?
- Patients with perennial or seasonal allergic rhinitis, conjunctivitis, or asthma whose symptoms worsen in damp weather, near water-damaged buildings, or during outdoor activities involving soil or vegetation
- Individuals with poorly controlled asthma despite standard therapy, particularly if they live or work in mouldy environments
- Suspected allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma or cystic fibrosis presenting with wheezing, eosinophilia, pulmonary infiltrates, and elevated total IgE
- Occupational evaluation of workers in agriculture, composting, food processing, or water-damage remediation with new-onset respiratory symptoms
- Chronic urticaria or atopic dermatitis that has not responded to standard management and where fungal sensitisation is suspected, particularly Candida
- Assessment of atopic children or adults with multiple environmental allergies to determine whether mould contributes to their symptom burden
- Baseline evaluation before initiating environmental mould remediation or considering allergen immunotherapy
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
3–5 business days
Collection notes
Phlebotomy at a Quest draw site; no special preparation. Antihistamines and other allergy medications do not need to be withheld, as they do not affect serum IgE levels. Ideally, test before starting systemic corticosteroids or omalizumab if those therapies are planned.
Specimen requirements
Minimum 2 mL serum in a red-top or gel separator tube. Separate serum from cells and refrigerate or freeze if not analysed within 48 hours. Specific IgE is stable frozen for months.
What can affect Mold Allergy Panel results?
Systemic corticosteroids and other immunosuppressants can transiently lower IgE synthesis, potentially yielding false-negative or reduced-titre results; ideally test before starting such therapy or after a washout period.
Omalizumab binds free IgE, which can interfere with some assay platforms and make total IgE uninterpretable, though specific IgE results may remain valid; timing and assay method should be reviewed with the laboratory.
Helminth infections stimulate polyclonal IgE production, raising total IgE and sometimes cross-reacting in allergen assays; travel and exposure history should be considered when total IgE is disproportionately high.
Total IgE rises through childhood and is higher in atopic individuals; age-specific reference ranges should be applied, and isolated specific IgE positivity is more meaningful than total IgE in polysensitised patients.
Outdoor mould spore counts peak in late summer and autumn, but serum IgE persists for months after exposure, so testing can be performed year-round; symptom diaries improve interpretation.
Some mould allergens share epitopes, so co-sensitisation is common and does not always reflect independent clinical reactivity; component-resolved diagnostics (when available) can refine specificity.
What do Mold Allergy Panel results mean?
Elevated
One or more specific IgE results ≥0.35 kU/L confirm sensitisation to that mould. Alternaria and Cladosporium positivity typically indicate outdoor allergy; Penicillium and Aspergillus suggest indoor dampness. Aspergillus IgE above 0.35 kU/L with total IgE >1000 kU/L, eosinophilia, and compatible imaging raises the diagnosis of ABPA. Candida and Mucor sensitisation are less common and should be interpreted cautiously, correlating with exposure and symptom timing. Total IgE above the reference range in conjunction with multiple positive specific IgEs confirms atopy and supports the allergic aetiology of respiratory or cutaneous symptoms.
Normal
All specific IgE results <0.35 kU/L and total IgE within the age-adjusted reference range indicate no detectable IgE-mediated sensitisation to the tested moulds. This result does not exclude non-IgE-mediated reactions such as hypersensitivity pneumonitis or toxic responses to mycotoxins, nor does it rule out sensitisation to moulds not included in the panel.
Reduced
Specific IgE <0.10 kU/L and total IgE within the normal range make IgE-mediated mould allergy unlikely. Symptoms may be due to irritant effects of mould exposure (non-allergic rhinitis, hypersensitivity pneumonitis), infection, or other allergens not included in this panel. Consider expanded allergen testing, nasal cytology, or pulmonary function tests to identify alternative causes.
Note: IgE positivity demonstrates sensitisation but not necessarily clinical allergy; correlation with symptom timing, exposure history, and response to environmental control is essential. A negative result does not exclude mould as an irritant or exclude other immune-mediated mechanisms. Serial testing is rarely indicated, as IgE levels remain detectable for years. In suspected ABPA, this panel should be combined with chest imaging, eosinophil count, Aspergillus precipitins (IgG), and pulmonary function tests. Cross-reactivity among moulds is common, so multiple positives may reflect shared epitopes rather than independent allergies.
Frequently asked questions
The panel tests for IgE antibodies to Alternaria alternata, Aspergillus fumigatus, Cladosporium herbarum, Penicillium notatum, Candida albicans, and Mucor racemosus, alongside total IgE. These represent the most clinically significant indoor and outdoor fungal allergens.
How to access the Mold Allergy Panel test
The Mold Allergy Panel reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Agarwal R, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. (2013)
- Denning DW, et al. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J. (2006)
- Crameri R, et al. Fungi: the neglected allergenic sources. Allergy. (2014)
- American Academy of Allergy, Asthma & Immunology. Mold allergy: diagnosis and management — practice parameter update. (2020)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.